• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Lifeward Ltd.

    5/29/26 4:05:19 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    SD 1 zk2635454.htm SD


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM SD
    SPECIALIZED DISCLOSURE REPORT

    Lifeward Ltd.
    (Exact name of the registrant as specified in its charter)

    State of Israel
    (State or other jurisdiction of incorporation)
    001-36612
    (Commission file number)
                                                                     
    2 Cabot Rd., Hudson, MA
     (Address of principal executive offices) 
    01749
    (Zip Code)

    Almog Adar, Chief Financial Officer, telephone: +508.251.1154
    (Name and telephone number, including area code, of the person to contact in connection with this report)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:
     
    ☒   Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025

    ☐   Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ____________


    Section 1 - Conflict Minerals Disclosures
     
    Item 1.01 – Conflict Minerals Disclosure and Report
     
    Introduction

    This Specialized Disclosure Form (“Form SD”) of Lifeward Ltd. (the “Company,” “we,” or “us”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended (the “1934 Act”), for the reporting period from January 1, 2025 to December 31, 2025.
     
    The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified under the Rule are necessary to the functionality or production of those products. The specified minerals are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin and tungsten (collectively, the “Conflict Minerals” or “3TG”), that originated in the Democratic Republic of the Congo (“DRC”) and certain adjoining countries (collectively with the DRC, the “Covered Countries”), unless the Secretary of State in the future determines that additional derivatives are financing conflict in the Covered Countries.

    Per the Rule and the instructions to Form SD, the Company is required to conduct in good faith a reasonable country of origin inquiry regarding the Conflict Minerals that is reasonably designed to determine whether any of the Conflict Minerals originated in any of the Covered Countries, or are from “recycled” or “scrap sources” as defined in Form SD.  Following the country of origin inquiry, the Company must exercise due diligence on the source and chain of custody of such Conflict Minerals if the Company knows or has reason to believe that those Conflict Minerals originated in any of the Covered Countries and knows or has reason to believe that they may not be entirely from recycled or scrap sources.

    Conclusion Based on Reasonable Country of Origin Inquiry

    In accordance with the Rule, the Company has concluded in good faith that during the year ended December 31, 2025:


    •
    Certain of the Company’s operations manufactured, or contracted to manufacture, products (the “Covered Products”) for which the Conflict Minerals are necessary to the functionality or production of those products.

    •
    Based on the Company’s good faith reasonable country of origin inquiry regarding the Conflict Minerals that were used in the Company’s Covered Products in 2025, which was designed to determine whether any of the Conflict Minerals contained in the Company’s Covered Products originated in any of the Covered Countries and whether any of the Conflict Minerals contained in the Covered Products are or may be from entirely recycled or scrap sources, the Company has reason to believe the following: (i) the Conflict Minerals contained in its Covered Products may have originated in one or more of the Covered Countries; and (ii) such Conflict Minerals may not be from entirely recycled or scrap sources.

    On the basis of these conclusions, the Company proceeded to exercise due diligence with respect to the source and chain of custody of the Conflict Minerals contained in its Covered Products. The Conflict Minerals Report (the “CMR”) describing the Company’s due diligence efforts is attached as Exhibit 1.01 to this Form SD for the reporting period from January 1, 2025 to December 31, 2025.  In accordance with applicable guidance from the Securities and Exchange Commission, the Company is not required to obtain an independent private sector audit of its CMR for the year ended December 31, 2025.

    Conflict Minerals Disclosure

    A copy of the Company’s CMR is filed as Exhibit 1.01 hereto and is publicly available on the "Charters & Policies" under the “Corporate Governance” page in the “Investor Relations” section of the Company’s website at https://ir.golifeward.com/corporate-governance/charters-and-policies. Information contained on, or that can be accessed through, the Company’s website does not constitute a part of this Form SD or the attached CMR and is not incorporated by reference herein.
     

    Item 1.02 Exhibit
     
    A copy of the Company’s CMR is filed as Exhibit 1.01 to this Form SD.

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 - Exhibits
     
    Item 3.01 – Exhibits
     
    Exhibit 1.01 — Conflict Minerals Report of Lifeward Ltd. for the year ended December 31, 2025, as required by Items 1.01 and 1.02 of this Form SD


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    Lifeward Ltd.
    (Registrant)

    /s/ Almog Adar                                                  May 29, 2026
    Name: Almog Adar                                                  (Date)
    Title: Chief Financial Officer


    Get the next $LFWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    SEC Filings

    View All

    SEC Form SD filed by Lifeward Ltd.

    SD - Lifeward Ltd. (0001607962) (Filer)

    5/29/26 4:05:19 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Lifeward Ltd.

    S-8 - Lifeward Ltd. (0001607962) (Filer)

    5/20/26 5:01:03 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Lifeward Ltd.

    10-Q - Lifeward Ltd. (0001607962) (Filer)

    5/20/26 4:24:54 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

    Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

    5/19/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Reports First Quarter 2026 Financial Results

    Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

    5/15/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

    5/11/26 9:25:58 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rose Keith Dale was granted 15,000 units of Ordinary Shares, increasing direct ownership by 720% to 17,083 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    5/20/26 8:15:43 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    New insider Rose Keith Dale claimed ownership of 2,083 units of Ordinary Shares (SEC Form 3)

    3 - Lifeward Ltd. (0001607962) (Issuer)

    5/20/26 8:13:57 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    New insider Oramed Pharmaceuticals Inc. claimed ownership of 1,250,363 units of Ordinary Shares (SEC Form 3)

    3 - Lifeward Ltd. (0001607962) (Issuer)

    5/14/26 5:19:35 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward Reports First Quarter 2026 Financial Results

    Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

    5/15/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

    5/11/26 9:25:58 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

    Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

    3/13/26 8:00:00 AM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

    Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

    5/19/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Appoints Bob Marshall as Chairman of the Board

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

    12/19/25 4:05:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care